Pharmaceutical Executive February 3, 2023
Overcoming persistent barriers to health equity in oncology trials will require innovation and cooperation.
Health equity in clinical trials is becoming more and more understood across our industry. We have all read the sobering statistics about diversity and access, including the fact that less than 5% of adults in the United States have participated in a clinical trial; and of those, 75% are white.1 We also know what these numbers tell us: there is a lack of access to effective medical interventions for the very patients they are most intended to treat—compounding health disparities in underrepresented and excluded populations, having a limited understanding of the effects of the therapies we develop in the full population, and hindering innovation at a...